Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models

Folia Pharmacologica Japonica

Volumn 121, Issue 6, 2003, Pages 393-400

  Sugiyama, Atsushi ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Atrioventricular block; Halothane; Long QT syndrome; Monophasic action potential; Torsades de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CISAPRIDE; DOFETILIDE; HALOPERIDOL; HALOTHANE; NIFEKALANT; SPARFLOXACIN; SULPIRIDE;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; IN VIVO STUDY; LONG QT SYNDROME; NONHUMAN; QT INTERVAL; REFRACTORY PERIOD; REVIEW; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIPSYCHOTIC AGENTS; ANTITUBERCULAR AGENTS; CATION TRANSPORT PROTEINS; CISAPRIDE; DISEASE MODELS, ANIMAL; DOGS; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOROQUINOLONES; GASTROINTESTINAL AGENTS; HALOPERIDOL; HISTAMINE H1 ANTAGONISTS; LONG QT SYNDROME; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; SULPIRIDE; TERFENADINE; TORSADES DE POINTES;

EID: 0037782488     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.121.393     Document Type: Review

References (26)

1. Sugiyama A, Ni C, Arita J, Eto K, Xue YX and Hashimoto K: Effects of antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording. Toxicol Appl Pharmacol 139, 109-114 (1996)
2. Sugiyama A, Aye NN, Katahira S, Saitoh M, Hagihara A, Matsubara Y and Hashimoto K: Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 143, 89-95 (1997)
3. Sugiyama A, Aye NN, Katahira S, Hagihara A and Hashimoto K: Effects of magnesium sulfate on the canine cardiovascular system complicating astemizole overdose. J Cardiovasc Pharmacol 29, 795-800 (1997)
4. Sugiyama A and Hashimoto K: Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol 152, 261-269 (1998)
5. Usui T, Sugiyama A, Ishida Y, Satoh Y, Sasaki Y and Hashimoto K: Simultaneous assessment of the hemodynamic, cardiomechanical and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels 13, 49-57 (1998)
6. Sugiyama A, Takahara A and Hashimoto K: Electrophysiological, cardiohemodynamic and β-blocking actions of a new ultra-short acting β-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol 34, 70-77 (1999)
7. Satoh Y, Sugiyama A, Tamura K and Hashimoto K: Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters. Jpn J Pharmacol 81, 79-85 (1999)
8. Satoh Y, Sugiyama A, Tamura K and Hashimoto K: Effects of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. Jpn Circ J 64, 445-451 (2000)
9. Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R and Hashimoto K: Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model. Jpn J Pharmacol 83, 107-112 (2000)
10. Satoh Y, Sugiyama A, Tamura K and Hashimoto K: Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. Jpn J Pharmacol 83, 327-334 (2000)
11. Shiina H, Sugiyama A, Takahara A, Satoh Y and Hashimoto K: Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring. Jpn Circ J 64, 777-782 (2000)
12. Satoh Y, Sugiyama A, Chiba K, Tamura K and Hashimoto K: QT prolonging effects of sparfloxacin, a fluoroquinolone antibiotics, assessed in the in vivo canine model with the monophasic action potential monitoring. J Cardiovasc Pharmacol 36, 510-515 (2000)
13. Sugiyama A, Satoh Y and Hashimoto K: In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 173, 120-128 (2001)
14. Sugiyama A, Satoh Y and Hashimoto K: Electrophysiologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model. J Cardiovasc Pharmacol 38, 268-277 (2001)
15. Sugiyama A, Satoh Y and Hashimoto K: Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn J Pharmacol 87, 74-82 (2001)
16. Sugiyama A, Satoh Y, Shiina H, Takahara A, Yoneyama M and Hashimoto K: Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 38, 940-946 (2001)
17. Yoneyama M, Sugiyama A, Yoshida H, Satoh Y and Hashimoto K: Cardiovascular effects of L-158, 809, a new angiotensin type 1 receptor antagonist, assessed using the halothane-anesthetized in vivo canine model. Jpn J Pharmacol 89, 192-196 (2002)
18. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Kugiyama K and Hashimoto K: Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart, assessed using the halothane-anesthetized, in vivo canine model. Circ J 66, 857-862 (2002)
19. Takahara A, Sugiyama A, Satoh Y, Yoneyama M and Hashimoto K: Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol 460, 51-57 (2003)
20. Sugiyama A, Satoh Y, Takahara A, Nakamura Y, Shimizu-Sasamata M, Sato S, Miyata K and Hashimoto K: Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur J Pharmacol 466, 137-146 (2003)
21. Chiba K, Sugiyama A, Satoh Y, Shiina H and Hashimoto K: Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for Torsades. Toxicol Appl Pharmacol 169, 8-16 (2000)
22. Sugiyama A, Satoh Y, Shiina H, Takeda S and Hashimoto K: Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J Cardiovasc Pharmacol 40, 235-245 (2002)
23. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, Kobayashi Y and Hashimoto K: Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT prolonging drugs. Jpn J Pharmacol 88, 341-350 (2002)
24. Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Yoshida H and Hashimoto K: Pharmacological and electrophysiological characterization of junctional rhythm during radiofrequency catheter ablation of the atrioventricular node: possible involvement of neurotransmitters from autonomic nervous system. Circ J 66, 696-701 (2002)
25. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K and Hashimoto K: Comparison of in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug sematilide using the canine chronic AV block model. Circ J 66, 758-762 (2002)
26. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol 88, 414-421 (2002)